FDA
-
-
-
-
-
-
-
vTv Therapeutics to Participate in Upcoming May Investor Conferences
-
-
-
-
-
-
-
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
-
-
-
-
-
-
-
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
-
-
-
-
-
-
-
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
-
-
-
-
-
-
-
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
-
327,243 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

